4 analysts have shared their evaluations of Paragon 28 (NYSE:FNA) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.25, a high estimate of $18.00, and a low estimate of $17.00. Observing a 7.81% increase, the current average has risen from the previous average price target of $16.00.
Breaking Down Analyst Ratings: A Detailed Examination
In examining recent analyst actions, we gain insights into how financial experts perceive Paragon 28. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Maintains | Buy | $17.00 | - |
| Mike Matson | Needham | Maintains | Buy | $17.00 | - |
| Matt O'Brien | Piper Sandler | Maintains | Overweight | $18.00 | - |
| Mike Matson | Needham | Raises | Buy | $17.00 | $16.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Paragon 28. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Paragon 28 compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Paragon 28's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Paragon 28's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Paragon 28 analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Paragon 28's Background
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
Unraveling the Financial Story of Paragon 28
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Paragon 28 displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 17.58%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Paragon 28's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -32.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Paragon 28's ROE excels beyond industry benchmarks, reaching -10.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Paragon 28's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.17%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.